tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2024 Jun;30(6):1267-1270.
doi: 10.3201/eid3006.231454.
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Ryo Kinoshita, Sho Miyamoto, Shoko Sakuraba, Jun Sugihara, Motoi Suzuki, Tadaki Suzuki, Daisuke Yoneoka
We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).
Keywords: COVID-19; Japan; SARS-CoV-2; children; elderly; infant; maternal immunity; respiratory infections; seroepidemiology; seroprevalence; surveillance; vaccine-preventable diseases; viruses; zoonoses.
. 2024 Jun;30(6):1267-1270.
doi: 10.3201/eid3006.231454.
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Ryo Kinoshita, Sho Miyamoto, Shoko Sakuraba, Jun Sugihara, Motoi Suzuki, Tadaki Suzuki, Daisuke Yoneoka
- PMID: 38782366
- DOI: 10.3201/eid3006.231454
We assessed SARS-CoV-2 seroprevalence in Japan during July-August 2023, with a focus on 2 key age groups, 0-15 and >80 years. We estimated overall seroprevalence of 45.3% for nucleocapsid antibodies and 95.4% for spike antibodies and found notable maternally derived spike antibodies in infants 6-11 months of age (90.0%).
Keywords: COVID-19; Japan; SARS-CoV-2; children; elderly; infant; maternal immunity; respiratory infections; seroepidemiology; seroprevalence; surveillance; vaccine-preventable diseases; viruses; zoonoses.